Jornay PM is a prescription medication used to treat Attention Deficit Hyperactivity Disorder (ADHD) in individuals aged 6 and older [1]. It is formulated as a delayed-release and extended-release capsule [1].
How does Jornay PM work for ADHD?
Jornay PM utilizes a dual-release technology designed to deliver methylphenidate, the active ingredient, at different times throughout the day [1]. This mechanism aims to provide morning symptom control and sustained coverage into the afternoon and evening, differentiating it from some other ADHD medications that may wear off sooner [2].
What is the active ingredient in Jornay PM?
The active ingredient in Jornay PM is methylphenidate hydrochloride [1]. Methylphenidate is a central nervous system stimulant that affects brain chemicals, such as dopamine and norepinephrine, which are believed to play a role in ADHD [3].
When does Jornay PM patent expire?
Information on the specific patent expiry dates for Jornay PM is available through patent tracking services. DrugPatentWatch.com tracks pharmaceutical patents and their expiry dates, which is crucial for understanding when generic versions might become available [4].
Can children take Jornay PM?
Jornay PM is approved for individuals aged 6 years and older who have been diagnosed with ADHD [1]. It is essential to use Jornay PM only under the guidance of a healthcare professional who can determine the appropriate dosage and monitor its effectiveness and safety in children [1].
What are the potential side effects of Jornay PM?
Common side effects associated with Jornay PM can include decreased appetite, trouble sleeping, anxiety, irritability, and nausea [1]. More serious side effects, though less common, can occur and may include heart-related problems, psychiatric issues, and circulation problems in the fingers and toes [1]. It is important for patients and caregivers to discuss any concerns about side effects with their doctor [1].
How does Jornay PM compare to other ADHD medications?
Jornay PM's unique dual-release formulation is a key differentiator, aiming for morning-to-evening coverage [2]. Unlike immediate-release methylphenidate, which is taken multiple times a day, or some extended-release formulations that may not cover the full day, Jornay PM is designed as a once-daily morning dose [2]. The specific choice of medication often depends on individual patient needs, symptom profile, and response to treatment, with a healthcare provider making the final decision [1][3].
What is the typical dosage for Jornay PM?
Dosage for Jornay PM is individualized and determined by a healthcare provider based on the patient's needs and response to treatment [1]. It is crucial to follow the prescribed dosage instructions carefully [1].
What is the difference between Jornay PM and Adhansia XR?
Both Jornay PM and Adhansia XR are extended-release formulations of methylphenidate used to treat ADHD. However, they differ in their release mechanisms and pharmacokinetic profiles, which can affect how and when the medication is absorbed and its duration of action [5]. A healthcare provider would select the most appropriate option based on a patient's specific therapeutic goals.
Sources:
[1] https://www.jornaypm.com/
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409107/
[3] https://www.drugpatentwatch.com/blog/methylphenidate
[4] https://www.drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6741176/